ArticleFrontiers in oncology2021

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.

Jing Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.